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Abstract
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment
options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in
several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting
developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in
particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade,
represents an important first step in this direction.
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Background
Advanced melanoma has historically been a difficult dis-
ease to treat, owing to few systemic treatment options.
Over the past few years, however, scientific advance-
ments have resulted in the approval of novel therapeutic
approaches that have changed front-line management of
advanced melanoma, with immune checkpoint inhib-
ition generating arguably the most excitement in the
field of melanoma oncology and beyond. Pioneering
work by James Allison led to the development of ipili-
mumab [1, 2], a fully human monoclonal antibody
against cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), which was approved by the FDA in 2011 for
the treatment of patients with advanced melanoma.
Similarly groundbreaking work by Tasuku Honjo re-
sulted in the first description of the programmed death
1 (PD-1) receptor [3], which has since led to the devel-
opment of two anti-PD-1 antibodies: nivolumab and
pembrolizumab. Both antibodies received FDA approval
in 2014 for the treatment of advanced melanoma patients
following progression after BRAF-targeted therapy (for
those with BRAF V600-mutated melanoma) and after ipi-
limumab. Despite these exciting developments, there re-
mains much work to be done to improve treatment
outcomes, and combination immunotherapy seems to
hold the key to achieving this goal. CTLA-4 and PD-1
inhibit antitumor immunity via complementary, nonre-
dundant pathways [4], and preclinical models have sup-
ported that combined checkpoint blockade synergistically
improves antitumor responses compared to blockade of
either pathway alone [5–7]. Based on these observations,
phase 1 and 2 trials were conducted with combined
nivolumab and ipilimumab [8, 9]. Favorable results
from these early phase trials led to CheckMate 067, a
phase 3 study designed to evaluate the safety and effi-
cacy of nivolumab alone or nivolumab plus ipilimumab
in comparison with ipilimumab alone, in patients with
previously untreated metastatic melanoma [10]. The re-
cently published landmark results of this trial, as well
as its implications for the future of melanoma treat-
ment, will be discussed here.
Main text
As monotherapies, ipilimumab and nivolumab both
clearly show significant activity in the treatment of
advanced melanoma. The regulatory approval of ipilimu-
mab was based on phase 3 trial data showing significantly
increased median overall survival (OS) in previously
treated melanoma patients who received ipilimumab
compared to those who received an experimental pep-
tide vaccine alone (10.1 vs 6.4 months; hazard ratio
(HR) = 0.66; p = 0.003) [11]. Another phase 3 trial, this
time conducted in the first-line setting, showed that ipili-
mumab combined with dacarbazine improved survival
compared with dacarbazine alone [12]. With regards to
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the anti-PD-1 drugs, nivolumab was the first fully hu-
man monoclonal antibody against PD-1 to be evaluated
therapeutically. In a phase 3 trial, previously untreated
patients received nivolumab or dacarbazine, and nivolu-
mab treatment was associated with superior median
progression-free survival (PFS) (5.1 vs 2.2 months, p <
0.001) and OS at 1 year (72.9 vs 42.1 %, p < 0.001) [6].
In another phase 3 trial, patients previously treated
with ipilimumab received nivolumab or chemotherapy,
with the nivolumab group showing superior overall re-
sponse rate (ORR) (32 vs 11 %) and fewer grades 3 to 4
adverse events (9 vs 31 %) [13, 14].
While these data show that immunotherapy clearly
results in better treatment outcomes compared to
chemotherapy, it remains unclear which patients will
respond, and the need for predictive models and bio-
markers remains [15]. Much research has focused on
how to improve the efficacy of currently available im-
munotherapies. Combined immune checkpoint block-
ade with anti-CTLA-4 and anti-PD-1 agents represents
an important step in this direction, with published
phase 1 and phase 2 data indicating the therapeutic
promise of this combination. In the phase 1 dose-
escalation study of advanced melanoma patients receiv-
ing the combination of nivolumab and ipilimumab, the
updated ORRs for patients treated with concurrent
nivolumab plus ipilimumab were 42 to 43 %. Prolonged
duration of response was also seen, with OS rate of
85 % at 1 year and 79 % at 2 years [8, 16]. In the ran-
domized phase 2 study comparing nivolumab plus ipili-
mumab with ipilimumab alone in patients with BRAF
wild-type melanoma, ORR was 61 % with combination
therapy compared to 11 % with monotherapy, with
complete responses seen in 22 and 0 % of patients, re-
spectively [9]. PFS was significantly prolonged with
combination therapy (median not reached, compared
with 4.4 months in the ipilimumab alone group).
Treatment-related adverse events of grade 3 or 4 were
54 % of patients in the combination therapy group,
compared with 24 % in the ipilimumab alone group.
To confirm and extend these results, a double-blind,
multicenter phase 3 trial (CheckMate 067) was subse-
quently conducted. In this trial, the safety and efficacy
of nivolumab plus ipilimumab with nivolumab and ipi-
limumab monotherapies were compared, and results
were presented at the ASCO 2015 plenary session and
published in the New England Journal of Medicine [10].
CheckMate 067 enrolled 945 treatment-naïve patients
with advanced melanoma who were stratified according
to disease stage, BRAF mutation status, and pro-
grammed death ligand 1 (PD-L1) expression. Patients
underwent 1:1:1 randomization to three different arms:
(1) nivolumab 3 mg/kg every 2 weeks with ipilimumab-
matched placebo; (2) nivolumab 1 mg/kg every 3 weeks
with ipilimumab 3 mg/kg every 3 weeks for four doses,
followed by nivolumab 3 mg/kg every 2 weeks; or (3)
ipilimumab 3 mg/kg every 3 weeks for four doses with
nivolumab-matched placebo. The study was powered to
detect differences in PFS and OS for nivolumab plus
ipilimumab versus ipilimumab alone and nivolumab
alone versus ipilimumab alone; at a median follow-up
of 12 months, safety and efficacy data are reported
while OS data are at present insufficiently mature. The
median PFS for patients taking combination therapy
was significantly prolonged at 11.5 months compared
to 2.9 months with ipilimumab alone (HR 0.42 (0.31–
0.57)) and 6.9 months with nivolumab alone (HR 0.57
(0.43–0.76)). Although the study was not powered to
compare combination therapy with nivolumab alone,
an exploratory analysis was done which showed the
median PFS of the combination to be superior com-
pared to nivolumab alone (HR 0.74 (0.60–0.92)). In
addition, combination therapy seems to be superior
compared to nivolumab and ipilimumab monotherapies
based on ORR: 57.6 % of patients in the combination
group, 43.7 % in the nivolumab alone group, and 19 %
in the ipilimumab alone group. In addition, though the
impressive 80 % tumor regressions with combination
therapy observed in the phase 1 study was not repro-
duced here, there was still significant reduction in
tumor burden in the combination, nivolumab alone,
and ipilimumab alone groups of −51.9, −34.5, and
−5.9 % from baseline, respectively.
PFS data stratified by patient subgroups are also pre-
sented; while BRAF mutation status and metastatic bur-
den subgroups all showed benefit from combination or
nivolumab monotherapy compared to ipilimumab alone,
the data stratified by PD-L1 expression are of particular
interest. In the phase 2 trial, a cutoff of ≥ 5 % was used
to determine PD-L1 positivity. Results from that trial
noted an ORR of 58 % for patients on combination ther-
apy whose tumors were PD-L1-positive, compared with
55 % in those whose tumors were PD-L1-negative. In
CheckMate 067, an identical cutoff point for PD-L1
positivity was used though differences in ORR as well as
PFS were observed between treatment groups. Patients
with PD-L1-positive tumors treated with combination,
nivolumab, and ipilimumab had ORRs of 72, 58, and
21 %, respectively (which translated to a PFS benefit as
well, with median PFS of 14, 14, and 3.9 months, re-
spectively). For those patients with PD-L1-negative tu-
mors, ORRs were 55, 44, and 18 %, respectively (PFS of
11.2, 5.3, and 2.8 months, respectively).
These improved results with combination therapy;
however, this did not come without cost. Although no
new safety signals were identified, increased toxicity was
seen in the combination group: grades 3–4 adverse
events occurred in 55 % of patients, compared to 16.3 %
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in patients treated with nivolumab alone, and 27.3 % of
patients treated with ipilimumab. Treatment-related ad-
verse events leading to therapy discontinuation occurred
in 36.4, 7.7, and 14.8 % of patients, respectively (most
commonly diarrhea, fatigue, and pruritus).
So, what are some important lessons we can take away
from CheckMate 067? Firstly: this data is extremely
promising and offers hope for improved treatment for
patients with advanced melanoma. However, this data
remains preliminary at this point; OS data will hopefully
be forthcoming and help illuminate whether combined
immune checkpoint blockade in the first-line setting
should be the new standard. Assuming for the moment
that OS data correlates with the PFS data, the informa-
tion from this trial could be practice-changing: given the
significant improvements in ORR and PFS in the com-
bination and nivolumab alone groups over ipilimumab
alone, ipilimumab alone should no longer be used in the
front-line setting. An anti-PD-1 agent or, arguably, com-
bined anti-PD-1 and anti-CTLA-4 blockade, should be
considered as the first-line therapy.
It is important to note, however, that although the
combination of nivolumab and ipilimumab showed im-
provement in ORR and PFS over nivolumab alone, that
the study was not designed specifically to show this dif-
ference and more guidance is needed to clarify who will
benefit from which upfront therapy. The subgroup ana-
lysis with PD-L1 expression does offer some insight into
patterns of response. PD-L1-positive patients who re-
ceived combination or nivolumab alone had the same
PFS of 14 months. PD-L1-negative patients who received
nivolumab alone had a lower PFS compared to those
who received combination therapy (5.3 vs 11.2 months).
Given this information, especially in light of the in-
creased toxicity with the combination, it may make
sense to tailor the treatment plan based on PD-L1 ex-
pression level. For example, PD-L1-negative patients
should receive combination therapy to maximize re-
sponse as long as they are able to tolerate the adverse
effects, while PD-L1-positive patients could have an
excellent response to nivolumab monotherapy and
avoid unnecessary toxicity. PD-1 monotherapy would
of course remain a valid option for any patient where
excess toxicity could be a concern, regardless of their
PD-L1 status. At this time, PD-L1 expression remains
an unvalidated biomarker, and research efforts are on-
going to identify biomarkers of response, particularly in
the tumor microenvironment.
Conclusion
In summary, this is an exciting time for melanoma re-
search. Updated data from CheckMate 067, as well as
results from other trials that are investigating combin-
ation immunotherapy, could move anti-PD-1 agents
and combinations thereof into the first-line treatment
setting. Longer follow-up and updated overall survival
data, as well as more correlative studies, are needed to
determine whether such a change is warranted.
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